CLINICAL HANDBOOK OF SCHIZOPHRENIA

642 IndexMotor symptoms, DSM-IV-TR,87Movement disorders,antipsychotic-induced, 392MRI. See Magnetic resonanceimagingMRS. See Magnetic resonancespectroscopyMultifactorial polygenic model,58Multiplex developmentaldisorder, in children, 483Multnomah Community AbilityScale, 138, 141characteristics and informationsources, 139tNAA. See N-AcetylaspartateNarcotics Anonymous, 154National Alliance on MentalIllness, 152, 302–304ACT and, 335in promotion of assertivecommunity treatment, 545,547National Association for RightsProtection and Advocacy,302National Association ofPsychiatric Survivors, 301National Association of StateMental Health ProgramDirectors, supported housingand, 296National Cholesterol EducationProgram, 132National Commission onCorrectional Health Care,356National Comorbidity Survey,617National Evidence-BasedPractices Project, 543training materials of, 544–545National Institute of ClinicalExcellence, guidelines of, 79–80National Institute of MentalHealthCommunity Support Programof, 309–310psychopharmacology study of,6psychotherapy study of, 6National Mental HealthConsumers’ Association,302Navane. See Thiothixine(Navane)Negative symptoms, 87–88, 107–108, 110–111behavioral reattribution and,237co-medications for, 193coping strategies for, 274tdefinitions of, 118examples of, 563PACE approach to, 386psychosocial interventions and,279treatment of, 149t, 151Neuroanatomical abnormalities,26–27, 36–37, 43Neurochemical hypotheses, 28–29Neurocognitive function, inassessment for early-onsetschizophrenia, 483–484Neurodevelopmental model, 18–19, 33, 45–47disease onset and, 95, 101–102obstetric complications and,71–72Neuroimaging, 8–9functional, 9–10Neuroleptic malignant syndrome,171Neuroleptics, quality of life and,588Neurological effects, clozapinerelated,182Neurological examination, withintellectual disability, 441–442Neuronal packing density,findings for, 49Neuropathology, 44–54cortical findings and, 47–50disease progression and, 52dysconnectivity and role ofwhite matter, 51–52future directions, 53global brain findings and, 46–47key points, 53neurodevelopmental model and,45–47research limitations, 52–53subcortical findings and, 50–51Neuroprotective agents, in PACEmodel, 387–388Neuropsychological assessment,97–98Neurosciencecognitive, 10–11of schizophrenia, history of, 7–12Neurotransmitters, 7–8role of, 39schizophrenia risk and, 27–28Newborn, EPS in, 475Nicotineimpact on schizophreniasymptoms, 460, 464neglect as target treatment, 464Nicotine dependence, cooccurring,127–128Nigrostriatal pathway, 28NMDA receptor, dysfunction of,29Nongovernmental organizations,health care functions indeveloping countries, 553NOTCH 4 gene, in AfricanAmericans versus EuropeanAmericans, 618Nottingham Health Profile, 585Novaco Anger Scale andProvocation Inventory, 401,403Nursing homes, 351Nutritional deficiencies, 19intellectual disability due to,439Obesity/overweightantipsychotic-induced, 172–173co-occurring, 131during pregnancy, SGAs and,476See also Weight gainObsessive–compulsive disorder,192clozapine for, 180, 182cognitive therapy for, 228PACE approach to, 386Obstetric complications, 65–73key points, 72neurodevelopmental hypothesisand, 18–19and neurodevelopmental model,71–73research on, 65–67types of, 67–71Occupational deficits, treatmentof, 149tOccupational functioning,interventions for, 153Olanzapine, 7, 30for COS/EOS, 487cost-effectiveness of, 511–512discontinuation of, 168–169dosing of, 165tsmoking and, 166metabolism of, 166tduring pregnancy, 476advantages/disadvantages/metabolic change, 475t